MUC-1 CD40L dendritic cell vaccine / MicroVAX - LARVOL DELTA

First-in-man study of Ad-sig-hMUC1/ecdCD40L vaccine for immunotherapy of MUC1 overexpressing epithelial cancers. (ASCO 2018) - P1; "This first-in-man study of Ad-sig-hMUC-1/ecdCD40L vector vaccine in cancers expressing MUC1 has demonstrated low toxicity and encouraging antitumor activity. Our data supports further clinical evaluation in a larger study cohort."

IO biomarker • Breast Cancer • Lung Cancer • Ovarian Cancer